Fig 1. PI3K/AKT/mTOR signaling pathway showing interacting activation and regulatory feedback loops. Adapted from Hoeffer and Klann. 35 Mammalian target of rapamycin (mTOR) is a serine-threonine ...

The PI3K/Akt/mTOR pathway has a central role in cancer metastasis and radiotherapy. To develop effective therapeutics to improve radiosensitivity, understanding the possible pathways of ...

Deregulation of the PI3K/Akt/mTOR pathway contributes to cancer cell survival, promotes chemotherapy resistance through disruption of apoptosis and initiates cap-dependent translation of mRNAs ...

Combining SFN AZ significantly inhibits the PI3K/Akt/mTOR pathway and significantly reducing 5-HT secretion in carcinoid syndrome Oncotarget published "Next-generation multimodality of ...

Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. JCO 27 , 857-871 (2009). DOI: ...

Gliomas are among the deadliest brain tumors, with limited treatment options and poor survival rates. Scientists from China ...

Research Progress on Signaling Pathways of LGALS1 in Malignant Tumors. Journal of Biosciences and Medicines, 13, 142-155. doi: 10.4236/jbm.2025.136013 . Malignant tumors, commonly referred to as ...

Piqur Therapeutics has now raised more than $42 million for its work on small molecule therapies that target the PI3K-Akt-mTOR pathway and has the money to take its lead drug to Phase II.

Tine Cuppens et al. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative.

Intellikine, a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk Chief Medical Officer Appointment Strengthens Intellikine's Development Expertise and ...